Erasca, Inc. (NASDAQ: ERAS) is highlighted as one of the 12 hot penny stocks to invest in right now. Analysts are confident in ERAS due to advancements in their pipeline and positive Q3 2025 results, with a $5 price target set by Guggenheim’s analyst Michael Schmidt.

In their Q3 2025 results, Erasca, Inc. reported a net loss of $30.6 million, or $0.11 per share, but closed the quarter with a strong cash position of $362.4 million. R&D expenses decreased, providing a runway into 2028.

Erasca, Inc. has gained analyst confidence with progress in various programs, including U.S. patent issuance for ERAS-0015 and development of ERAS-4001. Their upcoming Phase 1 readouts in 2026 are highly anticipated.

Erasca, Inc. is a clinical-stage precision oncology company focused on developing therapies targeting the RAS/MAPK pathway. The company’s management is optimistic about long-term growth, citing pending clinical milestones and a robust patent portfolio.

While ERAS shows investment potential, some AI stocks may offer greater upside with less downside risk. For those interested in undervalued AI stocks, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results